IRB #

STUDY00015911

Title

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

This study is being done to test the good and bad effects of PEGPH20 in combination with Pembrolizumab in men and women with hyaluronan-high non-small cell lung cancer or gastric adenocarcinoma.

Medical Condition(s)

Non-small cell lung cancer (NSCLC)
Gastric Adenocarcinoma

Eligibility Criteria

1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 89

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. After the last dose of the study drug, participants will be contacted by phone every 12 weeks until the end of the study, which is planned to be in two years.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Halozyme, INC

Recruitment End

12/31/2018

Compensation Provided

No


Go Back